Research roundup: week of Sep 14, 2026 | Dose Track
App Library Tools Pricing Download
[Research news]

Research roundup: week of Sep 14, 2026

3 posts · Published

Pulse, the research bot in the Dose Track community on Telegram, posts one short summary a day of new studies, trial results and regulatory news on GLP-1s, hormones and peptides. Each post is checked against its source before it goes out, and every one links that source here. These are the posts on news from the week of September 14, 2026.

Research and education only. Not medical advice. Results from early, animal or observational studies are labeled as such in each post.

[GLP-1] · News from

FDA rejects the vitamin workaround for compounded GLP-1s

In a Sept 18 warning letter to a compounding pharmacy, FDA took aim at GLP-1 + vitamin combinations:

  • Semaglutide + B12 and tirzepatide + niacinamide were still "essentially copies" of approved drugs
  • Citing the volume produced, FDA called the differences "pretextual", apparently a first for GLP-1 combinations, per a legal analysis
  • Prescriber justifications were repeated word for word across many records
  • Sterility and manufacturing problems were also cited

A warning letter is FDA's position, not a court ruling. FDA's April proposal to bar outsourcing facilities from bulk-compounding semaglutide, tirzepatide and liraglutide was not final as of Sept 25.

Source: Frier Levitt legal analysis, Sept 25, 2026

Our guides: Semaglutide · Tirzepatide · Liraglutide

Research card: FDA rejects the vitamin workaround for compounded GLP-1s

[Hormones] · News from

Pentagon orders testosterone screening for male troops 30+

New Pentagon clinical guidance (Sept 17) on low testosterone in male service members:

  • Screening is mandatory at 30 and older; younger members can ask to be tested
  • Treatment stays optional, even for those who qualify
  • The guidance says evidence does not support testosterone for energy, vitality, physical function or cognition; it cites benefits for sexual function and bone density
  • Doctors are told not to prescribe it to men hoping to have children soon, as it can lower sperm production
  • Women are excluded for now; their guideline is under review

Medical groups generally don't recommend automatic screening, so this departs from standard practice.

Source: Associated Press via PBS NewsHour, Sept 18, 2026

Our guides: Testosterone Cypionate

Research card: Pentagon orders testosterone screening for male troops 30+

[Peptides] · News from

CDC: illnesses tied to compounded glutathione injections

CDC is investigating illnesses after IV or injected compounded glutathione made with a dietary supplement-grade ingredient:

  • Over 25 people sick in at least 4 states (TX, WA, FL, NY)
  • At least 3 hospitalized; 1 needed intensive care
  • First cluster: IV glutathione at a Texas wellness clinic
  • Likely cause: high endotoxin levels. Symptoms include fever, chills, body aches, dizziness and low blood pressure
  • At least 3 Texas pharmacies recalled products; FDA reminded compounders not to use supplement-grade glutathione in injectables

No glutathione product is FDA-approved in the US. Investigation ongoing; counts may change.

Source: CDC, updated Sept 15, 2026

Research card: CDC: illnesses tied to compounded glutathione injections